ReviewEuropean journal of nuclear medicine and molecular imaging2018
Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.
Review in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Volume Analysis of Brain Cognitive Areas in Alzheimer's Disease: Interim 3-Year Results from the ASCOMALVA Trial.Journal of Alzheimer's disease : JAD · 2020Trial
- Plasma phosphorylated tau biomarkers map onto [^18F]FDG PET hypometabolism: a voxel-wise study in a clinical cohort with CSF-confirmed AD subgroup analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Functional imaging constrained diffusion for brain PET synthesis from structural MRI.Medical image analysis · 2026Article
- Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions.Neurodegenerative disease management · 2026Review
- The Evolving Role of FDG-PET in Behavioral Variant Frontotemporal Dementia: Current Applications and Future Opportunities.International journal of molecular sciences · 2025Review
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- How the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil.Arquivos de neuro-psiquiatria · 2025Article
- Clinical validity and reproducibility of a visual rating scale for cingulate island sign in a real-world memory clinic: An FDG-PET/MRI study.European journal of neurology · 2025Article
- Neural correlates of executive dysfunction in alcohol use disorder: preliminary evidence fromFrontiers in psychology · 2025Article
- Assessing the metabolism of the olfactory circuit by use ofAlzheimer's research & therapy · 2024Article
- Article
- Genetic-based patient stratification in Alzheimer's disease.Scientific reports · 2024Article
- Alteration of medial temporal lobe metabolism related to Alzheimer's disease and dementia with lewy bodies.Alzheimer's research & therapy · 2024Article
- [Dementia with Lewy bodies: old and new knowledge - Part 1: clinical aspects and diagnostics].Der Nervenarzt · 2024Review
- Cerebral hypometabolism mediates the effect of stroke volume on cognitive impairment in heart failure patients.ESC heart failure · 2024Article
- Assessing network degeneration and phenotypic heterogeneity in genetic frontotemporal lobar degeneration by decoding FDG-PET.NeuroImage. Clinical · 2024Article
- Exploring research hotspots and emerging trends in neuroimaging of vascular cognitive impairment: a bibliometric and visualized analysis.Frontiers in aging neuroscience · 2024Article
- Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.Brain : a journal of neurology · 2023Article
- The use of neuroimaging techniques in the early and differential diagnosis of dementia.Molecular psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the clinical utility of FDG-PET as a diagnostic aid for differentiating Alzheimer's disease (AD; both typical and atypical forms), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and non-degenerative pseudodementia.
methodsA comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted on six different diagnostic scenarios using the Delphi method.
resultsThe level of empirical study evidence for the use of FDG-PET was considered good for the discrimination of DLB and AD; fair for discriminating FTLD from AD; poor for atypical AD; and lacking for discriminating DLB from FTLD, AD from VaD, and for pseudodementia. Delphi voting led to consensus in all scenarios within two iterations. Panellists supported the use of FDG-PET for all PICOs-including those where study evidence was poor or lacking-based on its negative predictive value and on the assistance it provides when typical patterns of hypometabolism for a given diagnosis are observed.
conclusionAlthough there is an overall lack of evidence on which to base strong recommendations, it was generally concluded that FDG-PET has a diagnostic role in all scenarios. Prospective studies targeting diagnostically uncertain patients for assessing the added value of FDG-PET would be highly desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.